CN102014954A - 花粉季开始后使用初次剂量的粘膜变应原-特异性免疫疗法 - Google Patents

花粉季开始后使用初次剂量的粘膜变应原-特异性免疫疗法 Download PDF

Info

Publication number
CN102014954A
CN102014954A CN2009801154343A CN200980115434A CN102014954A CN 102014954 A CN102014954 A CN 102014954A CN 2009801154343 A CN2009801154343 A CN 2009801154343A CN 200980115434 A CN200980115434 A CN 200980115434A CN 102014954 A CN102014954 A CN 102014954A
Authority
CN
China
Prior art keywords
allergen
dosage form
solid dosage
administration
allergens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801154343A
Other languages
English (en)
Chinese (zh)
Inventor
E·G·伍斯滕伯格
E-C·A·普切尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102014954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALK Abello AS filed Critical ALK Abello AS
Publication of CN102014954A publication Critical patent/CN102014954A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801154343A 2008-04-11 2009-04-08 花粉季开始后使用初次剂量的粘膜变应原-特异性免疫疗法 Pending CN102014954A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4440108P 2008-04-11 2008-04-11
DKPA200800533 2008-04-11
DKPA200800533 2008-04-11
US61/044,401 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (1)

Publication Number Publication Date
CN102014954A true CN102014954A (zh) 2011-04-13

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801154343A Pending CN102014954A (zh) 2008-04-11 2009-04-08 花粉季开始后使用初次剂量的粘膜变应原-特异性免疫疗法

Country Status (12)

Country Link
US (2) US9248097B2 (https=)
EP (1) EP2265285B1 (https=)
JP (2) JP5618981B2 (https=)
CN (1) CN102014954A (https=)
AU (1) AU2009235490B2 (https=)
BR (1) BRPI0911433A2 (https=)
CA (1) CA2720455A1 (https=)
DE (1) DE202008006598U1 (https=)
EA (1) EA019202B1 (https=)
ES (1) ES2406391T3 (https=)
MX (1) MX2010011012A (https=)
WO (1) WO2009124954A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20120100163A1 (en) * 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
US20120100164A1 (en) 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
CA3208225A1 (en) 2012-01-16 2013-07-25 Elizabeth Mckenna Compositions and methods for the treatment of hepatitic diseases and disorders
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
JP2015535829A (ja) 2012-09-21 2015-12-17 マッケーナ、エリザベス 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065146A (zh) * 2004-11-10 2007-10-31 阿尔克-阿贝洛有限公司 通过过敏反应疫苗的粘膜给药预防性治疗过敏反应的方法
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
CN101115504A (zh) * 2005-02-03 2008-01-30 阿尔克-阿贝洛有限公司 控制次要过敏原以便提高免疫疗法的安全性

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
PL194804B1 (pl) 1998-03-16 2007-07-31 Alk Abello As Zrekombinowany alergen, sposób przygotowywania zrekombinowanego alergenu, kompozycja farmaceutyczna oraz zastosowanie zrekombinowanego alergenu do przygotowywania leku do wywoływania odpowiedzi immunologicznej u osobnika i do przygotowywania leku do leczenia, zapobiegania lub osłabiania reakcji alergicznych
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
ATE414773T1 (de) 2000-11-16 2008-12-15 Alk Abello As Mutante allergene
CN1668737A (zh) 2002-05-16 2005-09-14 阿尔克-阿贝洛有限公司 重组Bet.V.1过敏原突变体及其方法和制备
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CA2554337A1 (en) 2004-02-06 2005-08-25 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
CA2556557A1 (en) * 2004-02-26 2005-09-09 Alk Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
WO2006050729A2 (en) 2004-11-10 2006-05-18 Alk-Abellò A/S Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1814516B1 (en) 2005-11-04 2012-12-26 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
CA2682054A1 (en) * 2007-03-28 2008-10-02 Alk-Abello A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065146A (zh) * 2004-11-10 2007-10-31 阿尔克-阿贝洛有限公司 通过过敏反应疫苗的粘膜给药预防性治疗过敏反应的方法
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
CN101115504A (zh) * 2005-02-03 2008-01-30 阿尔克-阿贝洛有限公司 控制次要过敏原以便提高免疫疗法的安全性

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAHL RONALD ETC: "《Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years》", 《JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY》 *
范鸣 编译: "《花粉过敏症预防疫苗片剂Grazax 在德国首次上市》", 《药学进展》 *

Also Published As

Publication number Publication date
BRPI0911433A2 (pt) 2016-07-26
EP2265285A1 (en) 2010-12-29
ES2406391T3 (es) 2013-06-06
EP2265285B1 (en) 2013-03-20
MX2010011012A (es) 2010-11-12
JP5618981B2 (ja) 2014-11-05
HK1147946A1 (en) 2011-08-26
EA019202B1 (ru) 2014-01-30
DE202008006598U1 (de) 2008-10-02
US9248097B2 (en) 2016-02-02
AU2009235490A1 (en) 2009-10-15
US20110142934A1 (en) 2011-06-16
AU2009235490B2 (en) 2013-10-24
EA201071182A1 (ru) 2011-06-30
WO2009124954A1 (en) 2009-10-15
US20140127298A1 (en) 2014-05-08
JP2011516521A (ja) 2011-05-26
CA2720455A1 (en) 2009-10-15
JP2015013891A (ja) 2015-01-22

Similar Documents

Publication Publication Date Title
JP5618981B2 (ja) 花粉シーズン開始後の初回投薬での粘膜のアレルゲン−特異的免疫療法
EP2436395A2 (en) An allergen dosage form
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
MXPA05009079A (es) Forma de dosificacion que tiene una matriz de sacarido.
US20060115499A1 (en) Liquid allergy vaccine formulation for oromucosal administration
AU2008231722B2 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
ES2370043T3 (es) Uso de una formulación de vacuna de la alergia coadyuvada para administración subcutánea.
HK1147946B (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
CN101340892A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
CN103933562A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
HK1110773B (en) Use of a liquid allergy vaccine formulation for oromucosal administration
HK1147215A (en) An allergen dosage form
HK1087008B (en) An allergen dosage form

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Holm Hess, Denmark

Applicant after: Alk Abello AS

Address before: Holm Hess, Denmark

Applicant before: Alk Abello AS

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ALK-ABELLO A/S TO: ALK-ABELL A/S

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413